Eli Lilly (NYSE:LLY) announced on Wednesday that its oral weight loss candidate, orforglipron, reached the main goals in two ...

Eli Lilly has built the case for its oral GLP-1 agonist orforglipron with two more phase 3 readouts, including new data ...

Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 ACHIEVE-2 and ACHIEVE-5 trials.

Eli Lilly's experimental oral weight-loss drug, orforglipron, demonstrated superior blood sugar control in diabetic patients ...

An epidemic of Type 2 diabetes continues to plague the United States, leading to calls for reassessing how the disease is ...

Metformin is a safe and effective oral medication for people with type 2 diabetes. Here's how it can help regulate ...

Hemoglobin A1C (HbA1C) or simply A1C is one of the commonly used tests to diagnose prediabetes, type 1 and type 2 diabetes, as well as the main test to help manage diabetes. This simple blood test ...

Authors say in those without diabetes, continuous glucose monitors are not a substitute for HbA1c. (HealthDay News) — Continuous glucose monitors (CGMs) do not accurately reflect blood sugar control ...

Hypothyroidism during pregnancy may have a negative metabolic impact in women with gestational diabetes, with high TSH levels ...

During November, the American Red Cross is partnering with National Diabetes Month to offer free hemoglobin A1C testing to ...

Eli Lilly (LLY) stock is in focus as the company's oral weight loss candidate orforglipron succeeds in two Phase 3 trials for ...